Hosted on MSN10mon
Amgen’s obesity drug puts stock on pace for best day since 2009 as analysts predict big gains to come
Amgen’s stock was on pace early Friday for its best day since 2009 — and analysts see more gains ahead as the company maps out late-stage trials for the drug. Amgen is “very encouraged” by ...
Amgen reports new data from Phase 3 registrational MINT trial of Uplinza
Amgen (AMGN) announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of Uplinza in adults living with ...